NDAORALSOLUTIONPriority Review
Approved
Mar 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
NORVIR (ritonavir) by AbbVie is [see microbiology ( ) ] . First approved in 1996.
Drug data last refreshed 13h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORVIR (ritonavir) is an oral protease inhibitor approved in 1996 for HIV infection and AIDS. It is primarily used as a pharmacokinetic booster in combination antiretroviral regimens to increase plasma concentrations of other protease inhibitors. Ritonavir has expanded indications including hepatitis C, COVID-19, and HIV-associated complications.
$753KPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Part D claims (1,933 in 2023), signaling a small and shrinking commercial footprint requiring defensive rather than growth-oriented strategies.
Mechanism of Action
[see Microbiology ( ) ] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients
HIV Infections
The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir
18 enrolled
HIV Infections
The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma
Sarcoma, KaposiHIV Infections
Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
8 enrolled
HIV Infections
Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants
31 enrolled
HIV Infections
Worked on NORVIR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.